Abstract. Several alpha emitting isotopes have been proposed for radioimmunotherapy. To produce these nuclides reliably and in quantities needed, unique manufacturing approaches will be required. This paper describes the approaches that are being developed for the manufacture of 225 Actinium ( 225 Ac) that decays to 213 Bismuth ( 213
The alpha-emitters 212 Bi, 213 Bi, 225 Ac, 211 At, and 223 Ra have very high cytotoxicity, high linear energy transfer, short path lengths (50-80 µm) and comparatively short radioactive halflives. These properties along with their ability to conjugate with antibodies provide the potential for a breakthrough in radioimmunotherapy. The radiolabeled conjugates of these alpha emitters can selectively kill cancer cells and [1] [2] the absorbed dose ratios for cancer sites to whole body are far higher than for beta particles.
The most promising alpha particles appear to be 213 Bi (t 1/2 =46 min) and 225 Ac (t 1/2 =10 days). These alpha emitters have been extensively studied in pre-clinical evaluations [3] [4] [5] and physician sponsored clinical trials [2, 6] as promising radioimmunotherapeutic drugs.
In 1997 Memorial Sloan Kettering Cancer Center (MSKCC) developed generators to supply 213 Bi and initiated the first human clinical trial with 213 Bi labeled antibodies. This trial treated patients diagnosed with Acute Myeloid Leukemia (AML). The results of the trial indicated that the unique nature of the alpha particles' high mass and energy in direct proximity to the cancer cell selectively killed individual cancer cells with minimal side effects to the patient.
Continuing studies at MSKCC have demonstrated the feasibility of using alpha radioisotopes to treat cancers such as those of the lung, prostate and breast. The treatment -Alpha Particle Immunotherapy (APIT) -combines the potent killing power of alpha particle-emitting radioactive atoms (   213   Bi or 225 Ac) with specific monoclonal antibodies to target cancer cells. In a clinical study, MSKCC treated 18 patients with AML in a dose-escalated study using 213 Bi. In this study, the therapy successfully eliminated large numbers of tumor cells without significant clinical side effects to the patient [6] . This study also demonstrated the safety, feasibility, and antileukemic effects of 213 Bi-HUM195 and resulted in the first proof-of-concept for systemtargeted alpha particle immunotherapy to treat humans.
Concomitantly with the clinical study being performed at MSKCC, the processes and controls necessary to commercially manufacture these radionuclides for radioimmunotherapeutic drugs are being developed. Commercialization of the radioimmunotherapeutic drug will require a reliable, sufficient, and economic supply of the radiochemical 213 Bi. Ra will produce over 1 Ci of 225 Ac in two days [10] . MedActinium, Inc. is currently evaluating the feasibility of this process for potential commercial production. In addition, AlphaMed, Inc. and DOE, through a process developed by the Massachusetts Institute of Technology is investigating a method of producing 225 Ac using a linear accelerator and photon excitation of 226 Ra [11] .
Researchers from the Missouri University (MU), the Missouri University Research Reactor (MURR), MedActinium, Inc. and Los Alamos National Laboratory (LANL) are working on a collaborative effort [12] Bi can be extracted.
This research involves both computational models to predict 229 Th production and experimental irradiations at the MURR followed by gamma spectroscopy analysis, to measure actual production rates. Irradiations are carried out in the graphite reflector of the reactor at a thermal flux of approximately 7 x 10 13 n/cm 2 sec and an epithermal flux of 2 x 10 13 n/cm 2 sec. To date three 226 Ra samples have been irradiated: a 1.4 µg sample irradiated for 5 days, a 1.4 µg sample irradiated for 18 days and an 11 µg sample irradiated for 35 days. Gamma-ray spectral measurements are carried out postirradiation at times ranging from 3 days to 150 days. Th has been insufficient to accurately measure and therefore, irradiations at the High Flux Irradiation Facility (HFIR) at ORNL are being considered.
As a further benchmark, 229 Th production has been compared to previous estimates assuming 25 day irradiations at the HFIR at ORNL at a thermal flux of 1 x 10 15 n/cm 2 sec and an epithermal flux of 4 x 10 14 n/cm 2 sec. Mirzadeh [13] Th. The disagreement between ORNL and MU results are primarily the result of differences in handling the cross sections in the calculations [14] . Additional verification of methods will likely reduce these differences.
If it is assumed that even the most conservative prediction of 1.8 mg of 229 Th production is valid, the calculational model predicts an equilibrium 229 Th production rate of approximately 1 mCi per day for a 10 gram 226 Ra sample irradiated at HFIR. Current production costs from ORNL (i.e. the extraction of 229 Th from 233 U) are $14,000 per mCi [8] . Thus, it appears that neutron irradiation will be cost effective with current practice.
Approaches to commercially manufacturing these radionuclides must include the availability to produce sufficient quantity for research, development, pre-clinical studies, physician trials, clinical trials with patients and commercial supply. This supply is estimated to increase by a factor of 100 over the next five years if other APIT therapies are developed for cancers such as Non Hodgkin's Lymphoma, prostrate, breast and others.
Production of 213 Bi or 225 Ac must be conducted using the applicable Food and Drug Administration (FDA) requirements (current Good Manufacturing Practices (cGMP). Commercialization of the radiopharmaceutical will require a cGMP source of the selected monoclonal antibody and bifunctional chelator as well. Conjugation of the radiometal to the antibody using the bi-functional chelator must also be performed under cGMP and must be stable in-vivo.
Finally, as required by the cGMP, the radiolabeled antibody must meet pre-determined specifications for yields, identity, chemical and radionuclidic purity, activity concentration, sterility and apyrogencity.
The rapid preparation of a short-lived alpha particle emitting radiopharmaceutical for commercial use must be manufactured under a comprehensive quality management system based on the cGMP as described in Title 21 of the Code of Federal Regulations part 210 and 211(21 CFR 210,211). To be effective the systems of the commercial organization must include a QA organization independent of production, defined roles and responsibilities for all personnel, documented and controlled processes and procedures, and adequate facilities and equipment.
MedActinium, Inc. is designing a commercial facility and equipment with approaches that will meet these stringent requirements. The Alpha Radiopharmaceutical Facility will be designed, built, and validated to produce radiopharmaceuticals for patient use and process the radioimmunotherapeutic drug under cGMP requirements.
Operations in the building will include the manufacture, testing, packaging, distribution, and marketing of radiochemicals and radiopharmaceuticals. The facility is designed to meet FDA's cGMP for design and construction and will also meet the radiological and environmental regulations of the State of Tennessee. The Alpha Radiopharmaceutical Facility, and associated equipment and personnel, will give MedActinium, Inc. the capacity to reliably supply its customers with radiochemicals and radiopharmaceuticals that meet regulatory and quality requirements.
Key equipment in the Alpha Radiopharmaceutical Facility will include alpha containment gloveboxes and alpha containment shielded manipulator cells.
Despite the radiological hazards associated with materials contaminated by 228 Th, MedActinium's automated separation process can and will consistently produce quality-purified product.
The alpha containment shielded manipulator cells are another significant design concept. The concept is an isolated basement that provides boundary control and radiation shielding. Individual process rooms and shielded manipulator cells allow for control of the various grades of 229 Th and eliminate crosscontamination. This approach also allows for smaller shielded manipulator cells, reducing the area and materials contaminated, thereby reducing radioactive waste generation. The shielded manipulator cell ventilation system uses a novel negative pressure concept with internal HEPA/Carbon filter recirculation. This system continually removes airborne radioactive contamination and 220 Rn, but contains the contaminants within the shielded confines of the cell. In addition, the system allows for removal of the filters for maintenance thus protecting workers from radiological exposure.
Rapid separation of the 225 Ac from 229 Th must be done "just-in-time". The approach to maximizing 225 Ac is driven by the short halflife of both 225 Ac and its precursor 225 Ra (t 1/2 =14.8 days), which make it impractical to "stockpile" these materials for longer than a few weeks.
MedActinium, Inc. has licensed proprietary separation processes from the PG Research Foundation, Inc. that maximizes the quantity of 225 Ac recovered to meet growing medical needs. These processes involve specialty chromatographic-type ion exchange resins that effectively separate Th, Ra, and Ac from various impurities. Chromatographic separations are distinct with nearly quantitative recovery of the desired radiochemical constituents. Furthermore, the separations technique can be configured to meet specific order requirements. Importantly, system performance can be validated using surrogates (e.g., 232 Th and 226 Ra, spiked with 225 Ac) as needed An example of an actinium recovery process is shown Figure 1 below. This process has been validated using 229 Th acquired from ORNL and also through surrogate testing. In this flowsheet, the Th (IV) is stored in an (NH 4 Ac has approached radioactive steady state. At this point, the Th (IV)/SO 4 2-solution is eluted on a cation-exchange resin as primary separation column that retains the Ac (III) and Ra (II) nuclides while greater than 98% of the Th (IV) elutes. After rinsing with (NH 4 ) 2 SO 4 , the Ra (II) and Ac (III) are stripped using concentrated HNO 3 . Because trace Th (IV) may be present and because preservation of the 229 Th(IV) supply is critical, a guard column further removes Th (IV) impurities. The Th (IV) retained by the guard column may be recovered using the (NH 4 ) 2 SO 4 solution at and recombined with the original 229 Th(IV) stock solution.
The Ra (II) and Ac (III) mixture is subsequently separated and the Ac (III) is recovered in 0.10 M HCl, which is seamlessly integrated into the multicolumn selectivity inversion generator for 213 Bi. The Ra (II) in 6.0 M HNO 3 effluent from the Ac (III) purification may be recycled and used to strip future batches of Ra (II) and Ac (III) from the cation-exchange resin, as shown in Figure 2 Bi. However, the short half-life of 213 Bi presents unique challenges in administering consistent, high-quality radiopharmaceutical doses to the patient. By working with the medical customer and within the framework of FDA regulations, MedActinium has developed an automated prototype 213 Bi generator conjugation kit for use in a hospital setting. The kit aseptically extracts and purifies 213 Bi and remotely conjugates the mAb, which is then radiolabeled with the 213 Bi. The alpha particle immunotherapeutic construct is then purified and transferred to a syringe ready for patient use.
Manufacturing the alpha emitters for radioimmumotherapeutic drugs require unique and specialized processes that must provide an adequate supply of the radiochemical. The processes being evaluated include the use of existing 233 U stockpiles, cyclotrons or linear accelerators and reactors. cGMP supply of the antibody and chelaor as well as appropriate facilities and customized equipment are also being developed. 
